Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 840-846

  Huo, Xinying ^a   Zhang, Qi ^a   Liu, Angela M ^b   Tang, Cuiju ^a   Gong, Yongling ^a   Bian, Jianmin ^a   Luk, John M ^a,b   Xu, Zhi ^a   Chen, Jinfei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Doxorubicin resistance; Hepatocellular carcinoma; Mitogen activated protein kinase; Yes associated protein

Indexed keywords

DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN BCL XL; PROTEIN KINASE B; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-X PROTEIN; BUTADIENES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMONES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; NITRILES; PHOSPHOPROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84872788552     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2176     Document Type: Article

References (33)

1. Meza-Junco J, Montano-Loza AJ, Liu DM, et al: Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 38: 54-62, 2012.
2. Huppert P: Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging 36: 677-683, 2011.
3. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
4. Asghar U and Meyer T: Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56: 686-695, 2012.
5. Yin M and Zhang L: Hippo signaling: a hub of growth control, tumor suppression and pluripotency maintenance. J Genet Genomics 38: 471-481, 2012.
6. Chan SW, Lim CJ, Chen L, et al: The Hippo pathway in bio logical control and cancer development. J Cell Physiol 226: 928-939, 2011.
7. Zhao B, Li L, Tumaneng K, Wang CY and Guan KL A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 24: 72-85, 2010.
8. Urtasun R, Latasa MU, Demartis MI, et al: Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 54: 2149-2158, 2012.
9. Xu MZ, Chan SW, Liu AM, et al: AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30: 1229-1240, 2011.
10. Zhao B, Wei X, Li W, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761, 2007 (Pubitemid 350070721)
11. Overholtzer M, Zhang J, Smolen GA, et al: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103: 12405-12410, 2006. (Pubitemid 44267272)
12. Wang X, Su L and Ou Q: Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer 48: 1227-1234, 2012.
13. Dong J, Feldmann G, Huang J, et al: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: 1120-1133, 2007 (Pubitemid 47410268)
14. Zender L, Spector MS, Xue W, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267, 2006. (Pubitemid 43929093)
15. Steinhardt AA, Gayyed MF, Klein AP, et al: Expression of Yes-associated protein in common solid tumors. Hum Pathol 39: 1582-1589, 2008.
16. Xu MZ, Yao TJ, Lee NP, et al: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585, 2009
17. Liu LX, Lee NP, Chan VW, et al: Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 50: 1453-1463, 2009
18. Ikeda M, Okusaka T, Ueno H, et al: Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 72: 188-193, 2007 (Pubitemid 351161608)
19. Park SH, Lee Y, Han SH, et al: Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 6: 3, 2006.
20. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006. (Pubitemid 43980482)
21. Park JW, Koh YH, Kim HB, et al: Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 56: 1336-1342, 2012.
22. Wang P, Bai Y, Song B, et al: PP1A-mediated dephosphorylation positively regulates YAP2 activity. PLoS One 6: e24288, 2011.
23. Huang JM, Nagatomo I, Suzuki E, et al: YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene: Jun. 11, 2012 (Epub ahead of print).
24. Fernandez LA, Squatrito M, Northcott P, et al: Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 31: 1923-1937, 2012.
25. Bao Y, Nakagawa K, Yang Z, et al: A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem 150: 199-208, 2011.
26. Shimizu S, Narita M and Tsujimoto Y Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487, 1999 (Pubitemid 29258855)
27. Lee TL, Yeh J, Friedman J, et al: A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122: 1987-1998, 2008. (Pubitemid 351441187)
28. Basu S, Totty NF, Irwin MS, Sudol M and Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11: 11-23, 2003. (Pubitemid 36126587)
29. Lapi E, Di Agostino S, Donzelli S, et al: PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 32: 803-814, 2008.
30. Naci D, El Azreq MA, Chetoui N, et al: α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 287: 17065-17076, 2012.
31. Yang CL, Jiang FQ, Xu F and Jiang GX: ADAM10 over-expression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol 33: 1535-1541, 2012.
32. Jiao M and Nan KJ: Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 40: 461-468, 2012.
33. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J and Rivard N: MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79: 355-369, 2000.